

# PRESS RELEASE



## Hansa Biopharma Nomination Committee formed

Lund November 19, 2019. Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on May 22, 2019 and has the following composition:

- Erika Kjellberg Eriksson representing Nexttobe AB,
- Anna Sundberg representing Handelsbanken Funds
- Sven Sandberg representing Thomas Olausson and Gladiator
- Ulf Wiinberg, Chairman of the Board

The Chairman of the Board shall also summon the first meeting of the Nomination Committee.

The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees and any remuneration for committee work, election of the chairman of the AGM, election of auditors (if applicable) and fee for the auditors, and proposals for rules for appointing the Nomination Committee.

The proposals of the Nomination Committee will be presented in the notice of the Annual General Meeting 2020 and will be published on Hansa Biopharma's website.

Shareholders wishing to submit comments or proposals to the Nomination Committee may do so via e-mail to [ir@hansabiopharma.com](mailto:ir@hansabiopharma.com) or by letter to Hansa Biopharma, Nomination Committee, Box 785, 220 07 Lund, Sweden.

This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.

The information was submitted for publication, through the contact person set out below, at 8:00 a.m. (CET) on November 19, 2019.

### Contact information

Klaus Sindahl  
Head of Investor Relations  
Hansa Biopharma  
M: +46 (0) 709–298 269  
E: [klaus.sindahl@hansabiopharma.com](mailto:klaus.sindahl@hansabiopharma.com)

Rolf Gulliksen  
Head of Corporate Communications  
Hansa Biopharma  
M: +46 (0) 733–328 634  
E: [rolf.gulliksen@hansabiopharma.com](mailto:rolf.gulliksen@hansabiopharma.com)

### About Hansa Biopharma

Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.

The Company's lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under review for marketing authorization by EMA. Hansa's research and development program is advancing the next generation of the Company's technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.

Hansa Biopharma  
Scheelevägen 22  
SE- 223 63 Lund, Sweden  
Phone: +46 46 16 56 70  
[www.hansabiopharma.com](http://www.hansabiopharma.com)

Nasdaq OMX Stockholm  
Ticker: HNSA  
ISIN: SE 0002148817